Skip to main content

Advertisement

SpringerLink
Log in

Inflammation: Therapeutic Targets for Diabetic Neuropathy

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

There are still no approved treatments for the prevention or of cure of diabetic neuropathy, and only symptomatic pain therapies of variable efficacy are available. Inflammation is a cardinal pathogenic mechanism of diabetic neuropathy. The relationships between inflammation and the development of diabetic neuropathy involve complex molecular networks and processes. Herein, we review the key inflammatory molecules (inflammatory cytokines, adhesion molecules, chemokines) and pathways (nuclear factor kappa B, JUN N-terminal kinase) implicated in the development and progression of diabetic neuropathy. Advances in the understanding of the roles of these key inflammatory molecules and pathways in diabetic neuropathy will facilitate the discovery of the potential of anti-inflammatory approaches for the inhibition of the development of neuropathy. Specifically, many anti-inflammatory drugs significantly inhibit the development of different aspects of diabetic neuropathy in animal models and clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Edwards JL, Vincent AM, Cheng HT, Feldman EL (2008) Diabetic neuropathy: mechanisms to management. Pharmacol Ther 120(1):1–34

    Article  CAS  PubMed  Google Scholar 

  2. Nowicki M, Kosacka J, Serke H, Bluher M, Spanel-Borowski K (2012) Altered sciatic nerve fiber morphology and endoneural microvessels in mouse models relevant for obesity, peripheral diabetic polyneuropathy, and the metabolic syndrome. J Neurosci Res 90(1):122–131

    Article  CAS  PubMed  Google Scholar 

  3. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW, Group DER (2010) DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 10(4):276–282

    Article  PubMed Central  PubMed  Google Scholar 

  4. Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 7(10):573–583

    Article  CAS  PubMed  Google Scholar 

  5. Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, Drel VR (2007) High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 56(10):2598–2608

    Article  CAS  PubMed  Google Scholar 

  6. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813–820

    Article  CAS  PubMed  Google Scholar 

  7. Tecilazich F, Dinh T, Lyons TE, Guest J, Villafuerte RA, Sampanis C, Gnardellis C, Zuo CS, Veves A (2013) Postexercise phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in diabetic patients with lower extremity complications. J Vasc Surg 57(4):997–1005

    Article  PubMed  Google Scholar 

  8. Toyooka K, Fujimura H (2009) Iatrogenic neuropathies. Curr Opin Neurol 22(5):475–479

    Article  PubMed  Google Scholar 

  9. Kaley TJ, Deangelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145(1):3–14

    Article  CAS  PubMed  Google Scholar 

  10. Freehill MT, Shi LL, Tompson JD, Warner JJ (2012) Suprascapular neuropathy: diagnosis and management. Phys Sportsmed 40(1):72–83

    Article  PubMed  Google Scholar 

  11. Boykin RE, Friedman DJ, Higgins LD, Warner JJ (2010) Suprascapular neuropathy. J Bone Joint Surg Am 92(13):2348–2364

    Article  PubMed  Google Scholar 

  12. Tang CY, Fung B (2011) The last defence? Surgical aspects of gouty arthritis of hand and wrist. Hong Kong Med J 17(6):480–486

    PubMed  Google Scholar 

  13. Douglas EW (2011) Inflammatory mediators in diabetic neuropathy. J Diabetes Metab S5–004

  14. Bluher M, Unger R, Rassoul F, Richter V, Paschke R (2002) Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 45(2):210–216

    Article  CAS  PubMed  Google Scholar 

  15. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE (2003) Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163(4):1233–1243

    Article  CAS  PubMed  Google Scholar 

  16. Zent R, Pozzi A (2007) Angiogenesis in diabetic nephropathy. Semin Nephrol 27(2):161–171

    Article  CAS  PubMed  Google Scholar 

  17. Chavez JC, Almhanna K, Berti-Mattera LN (2005) Transient expression of hypoxia-inducible factor-1 alpha and target genes in peripheral nerves from diabetic rats. Neurosci Lett 374(3):179–182

    Article  CAS  PubMed  Google Scholar 

  18. Doss DJ, Kuruvilla R, Bianchi R, Peterson RG, Eichberg J (1997) Effects of hypoxia and severity of diabetes on Na, K-ATPase activity and arachidonoyl-containing glycerophospholipid molecular species in nerve from streptozotocin diabetic rats. J Peripher Nerv Syst 2(2):155–163

    CAS  PubMed  Google Scholar 

  19. Grafe P, Bostock H, Schneider U (1994) The effects of hyperglycaemic hypoxia on rectification in rat dorsal root axons. J Physiol 480(Pt 2):297–307

    CAS  PubMed  Google Scholar 

  20. Honma H, Gross L, Windebank AJ (2004) Hypoxia-induced apoptosis of dorsal root ganglion neurons is associated with DNA damage recognition and cell cycle disruption in rats. Neurosci Lett 354(2):95–98

    Article  CAS  PubMed  Google Scholar 

  21. Veves A, Donaghue VM, Sarnow MR, Giurini JM, Campbell DR, LoGerfo FW (1996) The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 39(3):344–348

    Article  CAS  PubMed  Google Scholar 

  22. Juranek JK, Geddis MS, Song F, Zhang J, Garcia J, Rosario R, Yan SF, Brannagan TH, Schmidt AM (2013) RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 62(3):931–943

    Article  CAS  PubMed  Google Scholar 

  23. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, Steck AJ (2001) TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56(10):1371–1377

    Article  CAS  PubMed  Google Scholar 

  24. Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Sanada M, Kawai H, Chan L, Yasuda H, Maegawa H, Kimura H (2011) Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 301(5):E844–852

    Article  CAS  PubMed  Google Scholar 

  25. Leung L, Cahill CM (2010) TNF-alpha and neuropathic pain—a review. J Neuroinflammation 7:27

    Article  PubMed Central  PubMed  Google Scholar 

  26. Liao YH, Zhang GH, Jia D, Wang P, Qian NS, He F, Zeng XT, He Y, Yang YL, Cao DY, Zhang Y, Wang DS, Tao KS, Gao CJ, Dou KF (2011) Spinal astrocytic activation contributes to mechanical allodynia in a mouse model of type 2 diabetes. Brain Res 1368:324–335

    Article  CAS  PubMed  Google Scholar 

  27. Ren PC, Zhang Y, Zhang XD, An LJ, Lv HG, He J, Gao CJ, Sun XD (2012) High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes. Brain Res Bull 88(4):332–337

    Article  CAS  PubMed  Google Scholar 

  28. Talbot S, Chahmi E, Dias JP, Couture R (2010) Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J Neuroinflammation 7(1):36

    Article  PubMed Central  PubMed  Google Scholar 

  29. Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR (2011) Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc 110(8):487–494

    Article  PubMed Central  PubMed  Google Scholar 

  30. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11(2):136–140

    Article  CAS  PubMed  Google Scholar 

  31. Shelbaya S, Amer H, Seddik S, Allah AA, Sabry IM, Mohamed T, El Mosely M (2012) Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur Rev Med Pharmacol Sci 16(2):176–182

    CAS  PubMed  Google Scholar 

  32. Cotter MA, Gibson TM, Nangle MR, Cameron NE (2010) Effects of interleukin-6 treatment on neurovascular function, nerve perfusion and vascular endothelium in diabetic rats. Diabetes Obes Metab 12(8):689–699

    Article  CAS  PubMed  Google Scholar 

  33. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A (2009) Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 94(6):2157–2163

    Article  CAS  PubMed  Google Scholar 

  34. Yu LN, Yang XS, Hua Z, Xie W (2009) Serum levels of pro-inflammatory cytokines in diabetic patients with peripheral neuropathic pain and the correlation among them. Zhonghua Yi Xue Za Zhi 89(7):469–471

    CAS  PubMed  Google Scholar 

  35. Kolla VK, Madhavi G, Pulla Reddy B, Srikanth Babu BM, Yashovanthi J, Valluri VL, Ramesh J, Akka J (2009) Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine 47(3):173–177

    Article  CAS  PubMed  Google Scholar 

  36. Bour-Jordan H, Thompson HL, Bluestone JA (2005) Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol 175(9):5649–5655

    CAS  PubMed  Google Scholar 

  37. Press R, Deretzi G, Zou LP, Zhu J, Fredman P, Lycke J, Link H (2001) IL-10 and IFN-gamma in Guillain–Barre syndrome. Network Members of the Swedish Epidemiological Study Group. J Neuroimmunol 112(1–2):129–138

    Article  CAS  PubMed  Google Scholar 

  38. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T, Doring A, Thorand B, Holle R, Giani G, Martin S, Meisinger C (2009) Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 32(4):680–682

    Article  PubMed  Google Scholar 

  39. Papanas N, Katsiki N, Papatheodorou K, Demetriou M, Papazoglou D, Gioka T, Maltezos E (2011) Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 62(4):291–295

    Article  CAS  PubMed  Google Scholar 

  40. Azenabor A, Ogbera AO, Adejumo NE, Adejare AO (2011) Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. J Res Med Sci 16(10):1298–1305

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Zubair M, Malik A, Ahmad J (2012) Plasma adiponectin, IL-6, hsCRP, and TNF-alpha levels in subject with diabetic foot and their correlation with clinical variables in a North Indian tertiary care hospital. Indian J Endocrinol Metab 16(5):769–776

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Lin CW, Hsu LA, Chen CC, Yeh JT, Sun JH, Lin CH, Chen ST, Hsu BR, Huang YY (2010) C-reactive protein as an outcome predictor for percutaneous transluminal angioplasty in diabetic patients with peripheral arterial disease and infected foot ulcers. Diabetes Res Clin Pract 90(2):167–172

    Article  CAS  PubMed  Google Scholar 

  43. Jeandrot A, Richard JL, Combescure C, Jourdan N, Finge S, Rodier M, Corbeau P, Sotto A, Lavigne JP (2008) Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia 51(2):347–352

    Article  CAS  PubMed  Google Scholar 

  44. Jude EB, Abbott CA, Young MJ, Anderson SG, Douglas JT, Boulton AJ (1998) The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 41(3):330–336

    Article  CAS  PubMed  Google Scholar 

  45. Zakareia FA (2008) Electrophysiological changes, plasma vascular endothelial growth factor, fatty acid synthase, and adhesion molecules in diabetic neuropathy. Neurosciences 13(4):374–379

    PubMed  Google Scholar 

  46. Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L (1998) Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care 21(6):1008–1013

    Article  CAS  PubMed  Google Scholar 

  47. Hussain MJ, Peakman M, Gallati H, Lo SS, Hawa M, Viberti GC, Watkins PJ, Leslie RD, Vergani D (1996) Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 39(1):60–69

    CAS  PubMed  Google Scholar 

  48. Vargas R, Rincon J, Pedreanez A, Viera N, Hernandez-Fonseca JP, Pena C, Mosquera J (2012) Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats. Brain Res 1453:64–76

    Article  CAS  PubMed  Google Scholar 

  49. Michalowska-Wender G, Adamcewicz G, Wender M (2007) Impact of cytokines on the pathomechanism of diabetic and alcoholic neuropathies. Folia Neuropathol 45(2):78–81

    CAS  PubMed  Google Scholar 

  50. Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B (2008) Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol 181(12):8753–8760

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Galloway C, Chattopadhyay M (2013) Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in type 2 diabetes. Cytokine 63(1):1–5

    Article  CAS  PubMed  Google Scholar 

  52. Bhangoo S, Ren D, Miller RJ, Henry KJ, Lineswala J, Hamdouchi C, Li B, Monahan PE, Chan DM, Ripsch MS, White FA (2007) Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain 3:38

    Article  PubMed Central  PubMed  Google Scholar 

  53. Rothman SM, Ma LH, Whiteside GT, Winkelstein BA (2011) Inflammatory cytokine and chemokine expression is differentially modulated acutely in the dorsal root ganglion in response to different nerve root compressions. Spine 36(3):197–202

    Article  PubMed  Google Scholar 

  54. Matsuda M, Kawasaki F, Inoue H, Kanda Y, Yamada K, Harada Y, Saito M, Eto M, Matsuki M, Kaku K (2004) Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract 66(Suppl 1):S121–123

    Article  CAS  PubMed  Google Scholar 

  55. Tuttolomondo A, La Placa S, Di Raimondo D, Bellia C, Caruso A, Lo Sasso B, Guercio G, Diana G, Ciaccio M, Licata G, Pinto A (2010) Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol 9:50

    Article  PubMed Central  PubMed  Google Scholar 

  56. Gottsater A, Ahren B, Sundkvist G (1999) The relationship between leptin and the insulin resistance syndrome is disturbed in type 2 diabetic subjects with parasympathetic neuropathy. Diabetes Care 22(11):1913–1914

    Article  CAS  PubMed  Google Scholar 

  57. Drel VR, Mashtalir N, Ilnytska O, Shin J, Li F, Lyzogubov VV, Obrosova IG (2006) The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 55(12):3335–3343

    Article  CAS  PubMed  Google Scholar 

  58. Negi G, Kumar A, Sharma SS (2011) Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 50(2):124–131

    CAS  PubMed  Google Scholar 

  59. Kumar A, Negi G, Sharma SS (2011) JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab 13(8):750–758

    Article  CAS  PubMed  Google Scholar 

  60. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107

    Article  CAS  PubMed  Google Scholar 

  61. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL, Group DER (2006) Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29(2):340–344

    Article  PubMed Central  PubMed  Google Scholar 

  62. NA (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (9131):837–853

    Google Scholar 

  63. Jensen TS, Backonja MM, Hernandez Jimenez S, Tesfaye S, Valensi P, Ziegler D (2006) New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 3(2):108–119

    Article  PubMed  Google Scholar 

  64. Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL, Ruboxistaurin Study G (2007) Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 30(10):2626–2632

    Article  PubMed  Google Scholar 

  65. Loesch A, Tang H, Cotter MA, Cameron NE (2010) Sciatic nerve of diabetic rat treated with epoetin delta: effects on C-fibers and blood vessels including pericytes. Angiology 61(7):651–668

    Article  CAS  PubMed  Google Scholar 

  66. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52(11):2251–2263

    Article  CAS  PubMed  Google Scholar 

  67. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS (2010) Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 58(3):585–592

    Article  CAS  PubMed  Google Scholar 

  68. Anand P, Shenoy R, Palmer JE, Baines AJ, Lai RY, Robertson J, Bird N, Ostenfeld T, Chizh BA (2011) Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 15(10):1040–1048

    Article  CAS  PubMed  Google Scholar 

  69. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38(5):846–854

    Article  CAS  PubMed  Google Scholar 

  70. Kellogg AP, Converso K, Wiggin T, Stevens M, Pop-Busui R (2009) Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol 296(2):H453–461

    Article  CAS  PubMed  Google Scholar 

  71. Kellogg AP, Wiggin TD, Larkin DD, Hayes JM, Stevens MJ, Pop-Busui R (2007) Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 56(12):2997–3005

    Article  CAS  PubMed  Google Scholar 

  72. Bishnoi M, Bosgraaf CA, Abooj M, Zhong L, Premkumar LS (2011) Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol Pain 7:52

    Article  PubMed Central  PubMed  Google Scholar 

  73. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA, Betancourt AM (2012) Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med 1(7):557–565

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Nirogi R, Jabaris SL, Jayarajan P, Abraham R, Shanmuganathan D, Rasheed MA, Royapalley PK, Goura V (2011) Antinociceptive activity of alpha4beta2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. Eur J Pharmacol 668(1–2):155–162

    Article  CAS  PubMed  Google Scholar 

  75. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK (2011) Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 661(1–3):15–21

    Article  CAS  PubMed  Google Scholar 

  76. Padi SS, Kulkarni SK (2008) Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol 601(1–3):79–87

    Article  CAS  PubMed  Google Scholar 

  77. Kosacka J, Nowicki M, Kloting N, Kern M, Stumvoll M, Bechmann I, Serke H, Bluher M (2012) COMP-angiopoietin-1 recovers molecular biomarkers of neuropathy and improves vascularisation in sciatic nerve of ob/ob mice. PLoS One 7(3):e32881

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Bianchi R, Cervellini I, Porretta-Serapiglia C, Oggioni N, Burkey B, Ghezzi P, Cavaletti G, Lauria G (2012) Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. J Pharmacol Exp Ther 340(1):64–72

    Article  CAS  PubMed  Google Scholar 

  79. Cohen KL, Harris S (1987) Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 147(8):1442–1444

    Article  CAS  PubMed  Google Scholar 

  80. Valsecchi AE, Franchi S, Panerai AE, Sacerdote P, Trovato AE, Colleoni M (2008) Genistein, a natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity. J Neurochem 107(1):230–240

    Article  CAS  PubMed  Google Scholar 

  81. Valsecchi AE, Franchi S, Panerai AE, Rossi A, Sacerdote P, Colleoni M (2011) The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol 650(2–3):694–702

    Article  CAS  PubMed  Google Scholar 

  82. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL (2012) Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 83(4):650–659

    Article  CAS  PubMed  Google Scholar 

  83. Stavniichuk R, Drel VR, Shevalye H, Maksimchyk Y, Kuchmerovska TM, Nadler JL, Obrosova IG (2011) Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation. Exp Neurol 230(1):106–113

    Article  CAS  PubMed  Google Scholar 

  84. Zhang YP, Eber A, Yuan Y, Yang Z, Rodriguez Y, Levitt RC, Takacs P, Candiotti KA (2013) Prophylactic and antinociceptive effects of coenzyme Q10 on diabetic neuropathic pain in a mouse model of type 1 diabetes. Anesthesiology 118(4):945–954

    Article  CAS  PubMed  Google Scholar 

  85. Tiwari V, Kuhad A, Chopra K (2011) Emblica officinalis corrects functional, biochemical and molecular deficits in experimental diabetic neuropathy by targeting the oxido-nitrosative stress mediated inflammatory cascade. Phytother Res 25(10):1527–1536

    Article  PubMed  Google Scholar 

  86. Shevalye H, Watcho P, Stavniichuk R, Dyukova E, Lupachyk S, Obrosova IG (2012) Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats. Diabetes 61(8):2126–2133

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The work was supported by grants from the National Natural Science Foundation of China (no. 81100597), the Natural Science Foundation Project of the Chongqing Science and Technology Commission (CSTC 2009BA5012), and the Natural Science Foundation of the Third Military Medical University (2012XJQ17, 2009XQN34).

Author information

Authors and Affiliations

  1. National Drug Clinical Trial Institution, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

    Jiyin Zhou & Shiwen Zhou

Authors
  1. Jiyin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiwen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiyin Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, J., Zhou, S. Inflammation: Therapeutic Targets for Diabetic Neuropathy. Mol Neurobiol 49, 536–546 (2014). https://doi.org/10.1007/s12035-013-8537-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-013-8537-0

Keywords

Search

Navigation